Patent 12071438 was granted and assigned to Keros Therapeutics on August, 2024 by the United States Patent and Trademark Office.
The invention relates to crystalline forms of an ALK2 inhibitor, methods of their preparation, and related pharmaceutical preparations thereof. The invention also relates to pharmaceutical uses of the crystalline forms.